Eliminating malaria to counter artemisinin resistance.

Malaria parasites in Southeast Asia have evolved to resist artemisinin, the most powerful drug available to treat the disease. This resistance threatens to unravel decades of progress in global malaria control, potentially causing hundreds of thousands of additional deaths if it spreads to Africa as previous drug resistances have done. The research team will test a strategy called targeted chemo-elimination: repeatedly treating entire communities with antimalarial drugs in areas where resistant parasites have been identified, regardless of whether individuals show symptoms. Over the course of the project, they will measure whether this approach reduces malaria cases, shrinks the parasite population, alters its genetic makeup, and slows or reverses the spread of resistance. They will also assess the safety, cost, and feasibility of the method. If proven effective, the approach could provide a practical toolkit for containing artemisinin resistance before it becomes widespread, preserving the effectiveness of the last line of defence against falciparum malaria and protecting millions of people who depend on artemisinin-based treatments.